The UK and US have agreed to a key commercial pact that will keep no levies on UK pharmaceutical exports going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to raise spending on drugs through the public health system. This pledge secures that import taxes on these vital products will remain at zero for a duration of three years.
This deal is in response to recent threats to hike tariffs on patented drug products, with increases discussed as high as 100%.
"This agreement between the Britain strengthens the international landscape for innovative medicines and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Commercial Significance
Drugs represent one of the Britain's most significant goods shipped to the United States, which is easily the largest destination for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of the third quarter, the UK exported medicines totaling £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that span.
"This deal protects work, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed UK Commitments
The agreement entails several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Previously, repayments exceeded 20%.
Broader Context
This agreement follows a ongoing row between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by claims that American patients were charged a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while major expansions have been directed toward American operations.
A senior figure acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
